Prestige Consumer Healthcare Inc. released its Fiscal 2025 Annual Report, showcasing a year of record performance with revenues reaching $1,138 million and adjusted diluted earnings per share of $4.52. The report highlighted an organic growth rate of 1.2% compared to 2024, driven by strategic investments and brand-building efforts.
The company demonstrated strong financial discipline, achieving $243.3 million in free cash flow for the fiscal year and reducing its leverage ratio to 2.4x, the lowest in its history. Capital allocation included over $50 million in share repurchases and the acquisition of rights to additional Hydralyte territories, reinforcing its commitment to shareholder value.
The annual report emphasized Prestige Consumer Healthcare's multi-year pipeline of new product development and successful long-term investments in the eCommerce channel. These initiatives, coupled with a diverse and predominantly domestic supply base, position the company for continued consistent performance in a dynamic market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.